KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EPS (Weighted Average and Diluted) (2016 - 2025)

Medpace Holdings' EPS (Weighted Average and Diluted) history spans 11 years, with the latest figure at $4.64 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 26.43% year-over-year to $4.64; the TTM value through Dec 2025 reached $15.27, up 20.9%, while the annual FY2025 figure was $15.28, 20.98% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $4.64 in Q4 2025 per MEDP's latest filing, up from $3.86 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.64 in Q4 2025 to a low of $1.06 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $2.44, with a median of $2.24 recorded in 2023.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 65.62% in 2021 against a maximum downside of 1.49% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.32 in 2021, then skyrocketed by 59.09% to $2.1 in 2022, then grew by 17.14% to $2.46 in 2023, then skyrocketed by 49.19% to $3.67 in 2024, then increased by 26.43% to $4.64 in 2025.
  • Per Business Quant, the three most recent readings for MEDP's EPS (Weighted Average and Diluted) are $4.64 (Q4 2025), $3.86 (Q3 2025), and $3.1 (Q2 2025).